Quarterly ResultMay 12, 2026, 04:03 PM
OptimizeRx Q1 Revenue $19.8M; Updates 2026 Revenue Guidance
AI Summary
OptimizeRx Corp. reported Q1 2026 revenue of $19.8 million, a 10% decrease year-over-year. Despite the revenue decline, the company narrowed its GAAP net loss to $(0.5) million and significantly increased non-GAAP net income to $2.7 million and adjusted EBITDA to $3.3 million. OptimizeRx updated its 2026 revenue guidance to $95-$100 million, while maintaining its adjusted EBITDA guidance at $21-$25 million. The company also completed a debt refinancing, expected to save $1.5 million annually in interest, and launched efficiency initiatives projected to save $3 million annually.
Key Highlights
- Q1 2026 revenue decreased 10% to $19.8 million.
- GAAP net loss narrowed to $(0.5) million from $(2.2) million year-over-year.
- Non-GAAP net income increased to $2.7 million, up from $1.5 million in Q1 2025.
- Adjusted EBITDA rose to $3.3 million, compared to $1.5 million in Q1 2025.
- Updated 2026 revenue guidance to $95-$100 million.
- Maintained 2026 adjusted EBITDA guidance at $21-$25 million.
- Paid off $2.7 million in term loan principal during Q1.
- Debt refinancing completed post-Q1, saving an estimated $1.5 million annually in interest.
- Operating efficiency initiatives launched post-Q1, targeting $3 million in annualized savings.